Last updated: May 20, 2026
Crinone, a progesterone vaginal gel, is marketed in the US for luteal phase support in assisted reproduction and for other progesterone-deficiency indications. The drug’s near-term outlook is tied to: (1) US payer and channel positioning versus competing progesterone products, (2) ongoing availability risk given product lifecycle maturity, and (3) the timing of any new reformulation or generic entry that could compress pricing. Public clinical-trial activity appears limited in the most recent years relative to earlier development waves, so the market’s forward trajectory is driven more by competitive substitution and coverage dynamics than by brand-new efficacy datasets.
What clinical trials have been conducted for Crinone (progesterone vaginal gel), and what is the latest status?
Short answer: Crinone’s core evidence base is largely established from earlier controlled studies of progesterone vaginal administration for fertility and luteal support. Recent public updates point to a mature product with limited new, registrational-grade trials disclosed.
How does Crinone’s evidence map to its labeled indications?
Crinone is positioned as a progesterone replacement delivered via the vaginal route. The clinical program historically focused on outcomes used in assisted reproduction settings, including pregnancy and implantation-related endpoints.
What trial phases matter most for a mature product?
For a product already marketed for years, the relevant question is whether new trials are designed for:
- New dosing regimens (dose optimization)
- New delivery formats (gel-to-gel comparisons, device/vehicle changes)
- New indications (expansion beyond existing labeled use)
- Bioavailability/biocomparability to enable generic or follow-on product approvals
When registrational-grade trials are not present in recent public disclosures, market direction typically depends on regulatory status, supply continuity, and competitive pricing.
Where do the most recent “signal” updates typically appear?
For established generics and legacy brands, the newest public changes usually show up as:
- FDA label updates or format changes
- Post-marketing observational studies
- Comparative effectiveness studies in fertility clinics
- Submissions tied to manufacturing changes
How big is the Crinone market today, and what are the drivers of demand?
Short answer: Crinone demand is driven by the volume of fertility treatment cycles that require luteal support and by patient/provider adherence to a progesterone delivery form (vaginal gel versus other routes). Pricing and coverage remain the main demand levers, with substitution risk from other progesterone products increasing as formularies tighten.
What is the demand model for Crinone-like progesterone products?
Key demand components:
- Number of IVF and related assisted reproduction cycles using luteal support protocols
- Share of protocols choosing vaginal gel formulations
- Payer preference and out-of-pocket affordability
- Clinic protocol stickiness and nurse/pharmacy dispensing workflows
- Safety/tolerability perceptions that influence switching (especially in patients sensitive to other routes)
What external factors affect progesterone vaginal product volumes?
- Growth in assisted reproduction procedure volumes
- Shifts toward rival progesterone formulations (oral, intramuscular, vaginal inserts)
- Formulary decisions by PBMs and health plans
- Drug acquisition costs and wholesaler pricing volatility
- Supply continuity and manufacturing reliability
What competitors most threaten Crinone’s share, and how does Crinone compare?
Short answer: The competitive set is other progesterone formulations used for luteal support and progesterone deficiency. The threat is substitution, not typically radical clinical differentiation, given that progesterone’s pharmacology is shared across routes.
Which progesterone products compete with Crinone in luteal support?
Competing categories include:
- Progesterone vaginal products (gels, suppositories, inserts)
- Progesterone intramuscular formulations
- Oral progesterone products used off-label or in alternative labeled settings depending on jurisdiction
- Market-channel rivals in fertility distribution
How do decision factors usually differ by route?
- Vaginal route: perceived convenience and local tolerability; competition in clinic preference
- Intramuscular route: clinic comfort with injection workflows and patient acceptance issues
- Oral route: adherence advantages but depends on tolerability and formulary acceptance
How does the patent estate for Crinone affect generic entry risk?
Short answer: Patent-driven exclusivity often matters less for an old, mature progesterone brand than for newer biologics or differentiated drugs, but patent expiration and FDA listing history can still determine whether follow-on products face fewer barriers.
What to look for in an Orange Book-style review for a legacy progesterone product
The key items that influence generic entry risk are:
- Active listing(s) tied to Crinone’s NDA
- Expiration dates for composition, formulation, and use patents
- Exclusivity blocks such as non-patent exclusivity
- Any blocking patents that have historically prevented generic approvals or triggered litigation
Because Crinone is already marketed and widely used, the practical outcome is that generic competition timing is often already “baked in” unless a late-arising reformulation or new use is patented.
When does Crinone lose exclusivity, and what is the generic launch calendar?
Short answer: For legacy marketed products, the relevant calendar is mostly the current state of patents and whether any reformulation or method-of-use exclusivities remain. Generic entry risk tends to track patent and exclusivity status rather than new clinical trial outcomes.
How to translate exclusivity to launch probability
Generic launch probability increases when:
- The latest patent listed for relevant claims has expired
- Any listed blocking patents are no longer in force
- No ongoing Paragraph IV litigation remains active in the relevant window
- Formulation and method-of-use barriers are cleared
What typically happens after generic launch for vaginal progesterone gels
Post-launch patterns often include:
- Price compression via multiple manufacturers
- Switching to lower acquisition-cost alternatives, especially for payer-covered patients
- Reduced margin for the legacy brand
- Higher emphasis on supply reliability and rebates
What is the FDA regulatory status of Crinone, including approvals and any recent label changes?
Short answer: Crinone’s regulatory posture is that of an established NDA product. The commercial path depends on ongoing compliance, manufacturing continuity, and any label changes that affect eligibility for reimbursement.
What matters in label changes for market projection?
Market projection can swing when labels change in ways that influence:
- Indication wording or patient eligibility
- Dosing regimen and administration guidance
- Contraindications that affect clinic protocol adoption
What to watch in post-marketing and compliance updates
- Manufacturing facility changes that affect supply
- Distribution disruptions that can accelerate substitution to competitors
- Safety communication changes that shift prescriber preference
What is the Crinone clinical pipeline now, and are there any new registrational trials?
Short answer: There is no clear, widely publicized new registrational development program for Crinone in the same way as for late-stage differentiated therapeutics. Any pipeline activity tends to be post-approval research, bioequivalence, or manufacturing comparability rather than new efficacy trials.
Where could new clinical activity still influence commercialization?
Even without new phase trials, commercial impact can come from:
- Real-world evidence studies demonstrating outcomes in fertility clinics
- Comparative studies that reduce uncertainty about switching between progesterone routes
- Studies supporting protocol standardization
How do market forecasts break down: volume, price, and share?
Short answer: A practical forecasting model for Crinone separates:
- Unit volume (fertility procedure demand times route preference)
- Net price (list price less rebates and payer discounts)
- Share shift (switching to competing progesterone products after price or availability changes)
Base-case drivers for the next 12 to 36 months
- Fertility volumes trend
- Formulary tightening and PBM preference
- Availability and supply stability (stock-outs can cause durable switching)
- Competitive promotions and channel incentives
Downside scenario drivers
- More aggressive generic pricing in vaginal progesterone gel segments
- Supply disruption
- Payer policies that narrow preferred progesterone formats
Upside scenario drivers
- Reimbursement support that sustains use of vaginal gel protocols
- Fewer availability disruptions and stable clinic adoption
- Limited competitive entry in specific geographies or pack sizes
What is the projected market trajectory for Crinone through major time horizons?
Short answer: For a mature progesterone gel brand, projections usually show: modest growth tied to fertility volumes, offset by price compression and share losses to competing products if generic or lower-cost alternatives expand. Market trajectory is therefore more “pressure-driven” than “innovation-driven.”
12-month projection (near-term)
Expected outcome pattern:
- Stable or slightly declining net price
- Volume growth tied to underlying fertility demand
- Share volatility depending on substitution pressure and availability
3-year projection (mid-term)
Expected outcome pattern:
- Continued net price compression if competitive products increase coverage
- Gradual share migration toward lowest acquisition-cost options
- Upside only if the brand retains formulary position and supply reliability
5-year projection (long-term)
Expected outcome pattern:
- Mature brand dynamics: market share stabilizes at the level supported by payer coverage and clinic protocol inertia
- If no major barriers exist to substitution, long-run revenue growth is limited and largely tied to market growth in assisted reproduction
Where is Crinone most exposed by geography?
Short answer: US represents the highest visibility and the most direct competition pressure via generic availability. Other markets depend on local approvals, reimbursement structures, and tender/wholesale purchasing patterns, which can accelerate or dampen price erosion.
US exposure profile
- High transparency via FDA listing activity and generic competitive dynamics
- PBM and payer controls that shape preferred product selection
Non-US exposure profile
- Procurement-driven pricing in many systems
- Manufacturing and regulatory continuity risk that affects supply consistency
What patent litigation or settlement dynamics affect Crinone?
Short answer: Patent litigation for a legacy progesterone product, if it occurred historically, typically has a bounded effect: it delays or blocks generic entry for defined periods. Current market risks are more likely linked to whether any remaining patent barriers exist for specific follow-on products.
How to interpret litigation impact for market modeling
- If no active litigation exists in the relevant window, the market impacts are already reflected in current generic availability.
- If litigation exists, it can delay launches and support higher net pricing.
What formulations of progesterone are protected, and does formulation matter commercially?
Short answer: For vaginal gels, formulation patents can influence entry if they cover composition, rheology, release characteristics, stability, and manufacturing process parameters. Commercially, even small product differences can affect switching if clinicians perceive tolerability advantages.
What formulation elements drive comparability scrutiny?
- Gel viscosity and spreadability
- Release rate and local exposure
- Bioavailability profiles in vaginal delivery systems
- Stability and shelf-life performance
- Packaging and dosing applicator compatibility
Key Takeaways
- Crinone is a mature progesterone vaginal gel franchise; near-term market direction is driven primarily by substitution pressure, payer coverage, and supply continuity rather than by new late-stage clinical outcomes.
- Forecasting hinges on unit demand in fertility protocols, net price compression from competitive progesterone products, and durability of clinic/payer preference for vaginal gel formats.
- Generic entry and patent estate effects are largely historical for a legacy brand; current risk is linked to whether any remaining barriers protect specific follow-on formats or dosing regimens.
- The most actionable commercial levers for market projection are price netting (rebates/discounting), formulary positioning, and availability risk.
FAQs
- What is Crinone used for in fertility treatment, and how is it positioned versus intramuscular progesterone?
- Does Crinone’s vaginal gel formulation face substitution risk from other vaginal progesterone products?
- How do PBM formulary decisions typically affect progesterone vaginal products after generic availability expands?
- What factors most influence whether clinics switch luteal support products in IVF protocols?
- How can supply disruptions change Crinone market share beyond short-term lost sales?
References (APA)
- FDA. (n.d.). Drugs@FDA: Crinone (progesterone) and related listings. US Food and Drug Administration.
- FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US Food and Drug Administration.
